TRANSMEDICS GROUP, INC. Financials TransMedics Group, Inc.
Equities
TMDX
US89377M1099
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 92.08 USD | +3.17% |
|
+9.41% | +16.66% |
| Apr. 18 | Transmedics Group Insider Sold Shares Worth $380,480, According to a Recent SEC Filing | MT |
| Apr. 05 | Transmedics Group Insider Sold Shares Worth $802,084, According to a Recent SEC Filing | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 402.3 | 540.5 | 532 | 1,970 | 2,577 | 3,025 | - | - |
| Enterprise Value (EV) 1 | 355.8 | 449.5 | 474.8 | 1,828 | 2,688 | 3,213 | 3,230 | 2,967 |
| P/E ratio | -8.06 x | -17.2 x | -12 x | -50.2 x | -103 x | -1,299 x | 206 x | 42.8 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 17 x | 21.1 x | 17.6 x | 21.1 x | 10.7 x | 8.24 x | 6.17 x | 4.72 x |
| EV / Revenue | 15.1 x | 17.5 x | 15.7 x | 19.6 x | 11.1 x | 8.76 x | 6.59 x | 4.63 x |
| EV / EBITDA | -12.5 x | -18.1 x | -12.6 x | -65.4 x | -131 x | 56.7 x | 28.9 x | 18.4 x |
| EV / FCF | -11 x | -14.6 x | -14.7 x | -31.7 x | -16.3 x | -33.6 x | 979 x | 23.7 x |
| FCF Yield | -9.12% | -6.83% | -6.82% | -3.16% | -6.13% | -2.98% | 0.1% | 4.21% |
| Price to Book | 7.37 x | 4.73 x | 7.85 x | 10.6 x | 18.8 x | 19.1 x | 15.3 x | 6.7 x |
| Nbr of stocks (in thousands) | 21,164 | 27,161 | 27,768 | 31,924 | 32,648 | 32,851 | - | - |
| Reference price 2 | 19.01 | 19.90 | 19.16 | 61.72 | 78.93 | 92.08 | 92.08 | 92.08 |
| Announcement Date | 3/17/20 | 3/2/21 | 2/23/22 | 2/22/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 23.6 | 25.64 | 30.26 | 93.46 | 241.6 | 366.9 | 490 | 640.4 |
| EBITDA 1 | -28.38 | -24.81 | -37.61 | -27.96 | -20.55 | 56.66 | 111.9 | 161.4 |
| EBIT 1 | -29.6 | -26.38 | -39.43 | -31.44 | -28.73 | 1.924 | 31.2 | 94.63 |
| Operating Margin | -125.42% | -102.91% | -130.29% | -33.64% | -11.89% | 0.52% | 6.37% | 14.78% |
| Earnings before Tax (EBT) 1 | -33.51 | -28.72 | -44.18 | -36.16 | -26.67 | 0.7439 | 25.9 | 98.23 |
| Net income 1 | -33.55 | -28.75 | -44.22 | -36.23 | -25.03 | -1.923 | 16.5 | 78.51 |
| Net margin | -142.12% | -112.13% | -146.11% | -38.77% | -10.36% | -0.52% | 3.37% | 12.26% |
| EPS 2 | -2.360 | -1.160 | -1.600 | -1.230 | -0.7700 | -0.0709 | 0.4470 | 2.152 |
| Free Cash Flow 1 | -32.45 | -30.72 | -32.38 | -57.72 | -164.9 | -95.6 | 3.3 | 125 |
| FCF margin | -137.48% | -119.82% | -107.01% | -61.76% | -68.24% | -26.05% | 0.67% | 19.52% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 2.95% | 77.44% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 20% | 159.22% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/17/20 | 3/2/21 | 2/23/22 | 2/22/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.37 | 9.668 | 15.88 | 20.52 | 25.68 | 31.38 | 41.55 | 52.46 | 66.43 | 81.17 | 83.77 | 88.42 | 94.16 | 100.6 | 110.7 |
| EBITDA 1 | -11.27 | -10.86 | -8.862 | -8.95 | -4.653 | -5.494 | 3.119 | 5.444 | 0.77 | 6.208 | 11.1 | 11.8 | 15.2 | 15.9 | - |
| EBIT 1 | -11.72 | -11.33 | -9.369 | -9.745 | -5.544 | -6.779 | -2.089 | -0.906 | -1.123 | 2.603 | 1.251 | 0.9935 | 1.381 | 3.155 | -1.23 |
| Operating Margin | -218.34% | -117.17% | -59% | -47.49% | -21.59% | -21.61% | -5.03% | -1.73% | -1.69% | 3.21% | 1.49% | 1.12% | 1.47% | 3.14% | -1.11% |
| Earnings before Tax (EBT) 1 | -12.95 | -12.65 | -10.56 | -11.5 | -7.407 | -6.701 | -2.625 | -0.98 | -26.93 | 3.863 | 3.276 | 2.59 | 2.022 | 3.157 | -1.03 |
| Net income 1 | -12.96 | -12.67 | -10.56 | -11.52 | -7.426 | -6.72 | -2.636 | -1.001 | -25.42 | 4.031 | 2.602 | 3.291 | 2.898 | 4.158 | -1.025 |
| Net margin | -241.38% | -131.03% | -66.51% | -56.15% | -28.91% | -21.42% | -6.34% | -1.91% | -38.27% | 4.97% | 3.11% | 3.72% | 3.08% | 4.13% | -0.93% |
| EPS 2 | -0.4700 | -0.4600 | -0.3800 | -0.4100 | -0.2500 | -0.2100 | -0.0800 | -0.0300 | -0.7800 | 0.1200 | -0.005770 | - | 0.005280 | 0.0456 | -0.0300 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 2/23/22 | 5/3/22 | 8/1/22 | 11/3/22 | 2/22/23 | 5/1/23 | 8/3/23 | 11/6/23 | 2/26/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 111 | 188 | 205 | - |
| Net Cash position 1 | 46.5 | 91 | 57.3 | 142 | - | - | - | 58 |
| Leverage (Debt/EBITDA) | - | - | - | - | -5.421 x | 3.324 x | 1.829 x | - |
| Free Cash Flow 1 | -32.5 | -30.7 | -32.4 | -57.7 | -165 | -95.6 | 3.3 | 125 |
| ROE (net income / shareholders' equity) | -137% | -36.3% | -51.5% | -28.4% | -15.4% | -13.8% | -11.2% | 17.4% |
| ROA (Net income/ Total Assets) | -45.5% | -22.3% | -30.8% | -17.6% | -5.09% | 1.85% | 4.06% | 7.25% |
| Assets 1 | 73.73 | 128.7 | 143.5 | 206 | 491.6 | -104.2 | 406.9 | 1,083 |
| Book Value Per Share 2 | 2.580 | 4.210 | 2.440 | 5.830 | 4.200 | 4.810 | 6.020 | 13.80 |
| Cash Flow per Share 2 | - | - | - | - | -0.4000 | -0.1800 | -0.3000 | - |
| Capex 1 | 0.17 | 0.46 | 3.52 | 11.9 | 152 | 105 | 21 | 22 |
| Capex / Sales | 0.7% | 1.77% | 11.63% | 12.74% | 62.84% | 28.62% | 4.29% | 3.44% |
| Announcement Date | 3/17/20 | 3/2/21 | 2/23/22 | 2/22/23 | 2/26/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
92.08
USD
Average target price
100.3
USD
Spread / Average Target
+8.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.66% | 3.02B | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B | |
| +26.76% | 32.03B |
- Stock Market
- Equities
- TMDX Stock
- Financials TransMedics Group, Inc.
